Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
Clinical Protocol: Administration of Neomycin Resistance Gene-Marked EBV-Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving a Bone Marrow Transplant for Relapsed EBV-Positive Hodgkin Disease.